A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer

Summary

The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation \[SC-CF\]) in combination treatment (all cohorts except Cohort 4) and to characterize the safety of amivantamab SC-CF (Cohort 4).

Eligibility

Age range

18+ years

Sex

All

Healthy volunteers

No

Interventions

• Drug
  Amivantamab

  Amivantamab will be administered subcutaneously by manual injection.

• Drug
  Lazertinib

  Lazertinib will be administered as an oral tablet.

• Drug
  Carboplatin

  Carboplatin will be administrated by IV infusion.

• Drug
  Pemetrexed

  Pemetrexed will be administered by IV infusion.

• Drug
  Direct Oral Anticoagulant (DOAC)

  DOAC will be administered orally.

• Drug
  Low Molecular Weight Heparin (LMWH)

  LMWH will be administered subcutaneously.

Locations (110)